Abstract:Chronic infection of hepatitis B virus (HBV) is still one of the public health concerns affecting human health. Although the prophylactic HBV vaccines was introduced over three decades ago, the total number of chronic hepatitis B (CHB) infection still accounts for 3.5% (257 million) of the world's population, with approximately 800000 annual deaths related to the viral infection. Currently, drugs including PEG-IFN and NAs are widely used in the treatment of HBV infection with certain degree of success. It is still difficult to achieve a high proportion of "clinical cure" with existing treatment methods. The presence of covalently closed circular DNA (cccDNA) in the infected hepatocytes is the underlying mechanism for the long-term HBV persistence and is also essential for off-therapy viral relapse. The current treatments have no or limited effects on the suppression of intrahepatic cccDNA. The availability for a reliable cccDNA quantification assay would facilitate the developmentof anti-viral drugs targeting cccDNA-targeting. In this review, we summarized the advantages and disadvantages of the existing methods for cccDNA quantitation. Specifically, the extraction method of Hirt DNA combined with Exonuclease V can effectively remove other forms of HBV DNA, and suitable for cccDNA extraction, but it needs to be further optimized. Southern blot is considered as the "gold-standard" method for cccDNA detection, but it is less sensitive and requires cumbersome procedures, making it an unlikely method for high-throughput screening used for drug development or for clinical applications. The PCR-based methods are more convenient and sensitive for cccDNA detection. However, the reliability of PCR-based method requires further optimization and validation. Different PCR-based methods were developed for quantitation of HBV cccDNA. They include selective qPCR, droplet-digital PCR, rolling circle amplification PCR, in situ PCR, invader assay, magnetic capture hybridization qPCR, etc. These PCR-based methods are widely used in clinical and laboratory research for quantitation of cccDNA. Efforts need to be made to minimize the interference from other forms of DNAs in the assays. More recently, hepatitis B core related antigen (HBcrAg)was found to be a novel marker of HBV, and its level in serum is highly correlated with intracellular cccDNA level. This biomarker, the HBcrAg level, can be used to indicate the suppression of cccDNA during different clinical antiviral therapies. The correlation needs further analysis with additional data sets. In summary, we present a review on the quantitation assays for HBV cccDNA. Such assays are important for drug developments and clinical applications for improved management of HBV infection related diseases. Performance and characteristics of various methods were compared with the areas of improvements for different assays.

Serum HBV RNA composition dynamics as a marker for intrahepatic HBV cccDNA turnover

Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection

Cytokines and Chemokines in HBV Infection

Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection

[The Potential Use of Serum HBV RNA to Guide the Functional Cure of Chronic Hepatitis B].

Serum HBV DNA Plus RNA Shows Superiority in Reflecting the Activity of Intrahepatic Cccdna in Treatment-Naïve HBV-infected Individuals.

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients

Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients

Application Value of Serum HBV RNA in Clinical Management of Chronic Hepatitis B

Serum HBV RNA levels among untreated adults with chronic hepatitis B in distinct immune phases and liver histopathology statuses

The Role of cccDNA in HBV Maintenance

Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review

Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs

Analysis of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA and Serum Viral Markers in Treatment-Naive Patients with Acute and Chronic HBV Infection.

Quantatitative Assays For Covalently Closed Circular Dna Of Hepatitis B Virus

In Situ Analysis of Intrahepatic Virological Events in Chronic Hepatitis B Virus Infection.

Characteristics of HBV Novel Serum Markers Across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

Influence of interferon and nucleos(t)ide analogues on HBV cccDNA and functional cure of chronic hepatitis B

A CRISPR-based system to investigate HBV cccDNA biology

Quantitative Analyses of Intrahepatic HBV Cccdna and Serum HBsAg in 54 Patients with Chronic Hepatitis B